MT10109L in the Treatment of Glabellar Lines
Completed · Phase 3 · Has a placebo group
Conditions studied: Glabellar Lines
In brief
To evaluate the safety and efficacy of MT10109L in the treatment of glabellar lines (GL) in participants with moderate to severe GL.
Key facts
- Study ID
- NCT03795922
- Run by
- Medy-Tox
- People needed
- 234
- Starts
- 2018-12-24
- Expected to finish
- 2021-01-25
- Last updated by the study team
- 2023-07-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Female participants must not be pregnant or planning to get pregnant and willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.
You may not qualify if…
- Known immunization or hypersensitivity to any botulinum toxin serotype.
- Any medical condition that may put the participant at increased risk with exposure to MT10109L including diagnosed myasthenia gravis, Eaton Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
- History of facial nerve palsy.
- Any uncontrolled systemic disease.
- Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study intervention).
- Anticipated need for surgery or overnight hospitalization during the study.
- Prior exposure to botulinum toxin of any serotype for any reason.
- Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery).
- Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation.
- Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
- Females who are pregnant, nursing, or planning a pregnancy during the study.
- Participants who plan for an extended absence away from the immediate area of the study site that would preclude them from returning for all protocol-specified study visits.
Where it is running
- Investigate MD — Scottsdale, Arizona, United States
- Art of Skin MD — Solana Beach, California, United States
- Weinkle Dermatology — Bradenton, Florida, United States
- Etre, Cosmetic Dermatology and Laser Center — New Orleans, Louisiana, United States
- Dermatology and Laser Surgery Center of New York — New York, New York, United States
- SkinSearch of Rochester, Inc. — Rochester, New York, United States
- M3 Wake Research, Inc. — Raleigh, North Carolina, United States
- Aventiv Research, Inc. — Dublin, Ohio, United States
- Westlake Dermatology & Cosmetic Surgery — Austin, Texas, United States
- Centre de la Fontaine — Loverval, Hainaut, Belgium
- Medical Skin Care — Sint-Truiden, Limburg, Belgium
- Universitair Ziekenhuis Brussel — Brussels, Belgium
- CHU Liege — Liège, Belgium
- Kazan State Medical University — Kazan', Tatarstan Republic, Russia
- Medical Centre Capital-Zdorovie — Moscow, Russia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.